TapewireFind a company

person · Reporting owner

Kihara James

Disclosed activity across 1 company

Tapewire entity
34940
SEC CIK
0001816160

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ACADIA PHARMACEUTICALS INCACAD · Entity 3913PRINCIPAL ACCOUNTING OFFICERJune 26, 2026June 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACADIA PHARMACEUTICALS INC

Report date June 26, 2026 · Filed June 29, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect13,088 Reported balance After 2026-06-26 transaction · row 1
1 source row

Row 1 · 2026-06-26 · Sale · Disposed 11,421 · Balance 13,088

F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 9, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.88 to $26.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Filing footnotes · ownership attribution and instrument terms

F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 9, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.88 to $26.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 26, 2026 Filed Jun 29, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 11,421 $26.08 $297,912.22
Disclosure

SEC source: 0001816160-26-000009 · form4-06292026_060601.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,088

F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 9, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.88 to $26.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
May 26, 2026 Filed May 27, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 5,401 $21.18 $114,393.18
Disclosure

SEC source: 0001816160-26-000008 · form4-05272026_060501.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,509

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.1801 to $21.185, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · balance_after: Includes 781 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.

Read SEC document
May 04, 2026 Filed May 5, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,332 $21.79 $29,024.28
Disclosure

SEC source: 0001816160-26-000007 · form4-05052026_060511.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,129

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.79 to $21.815, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
May 01, 2026 Filed May 5, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,596 $0.00 $0.00
Disclosure

SEC source: 0001816160-26-000007 · form4-05052026_060511.xml · derivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,596

Underlying: Common Stock · 2,596 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Read SEC document
May 01, 2026 Filed May 5, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,596 Not disclosed Not disclosed
Disclosure

SEC source: 0001816160-26-000007 · form4-05052026_060511.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,461

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
April 07, 2026 Filed Apr 7, 2026 23:55 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,030 $22.20 $22,866.00
Disclosure

SEC source: 0001816160-26-000005 · form4-04072026_110435.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,865

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.07 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
April 05, 2026 Filed Apr 7, 2026 23:55 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,010 $0.00 $0.00
Disclosure

SEC source: 0001816160-26-000005 · form4-04072026_110435.xml · derivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2026 Filed Apr 7, 2026 23:55 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,010 Not disclosed Not disclosed
Disclosure

SEC source: 0001816160-26-000005 · form4-04072026_110435.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,895

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 26, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 12 $21.73 $260.70
Disclosure

SEC source: 0001816160-26-000003 · form4-03262026_080304.xml · nonDerivative · entry 5

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,885

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
March 26, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,097 $21.65 $23,750.05
Disclosure

SEC source: 0001816160-26-000003 · form4-03262026_080304.xml · nonDerivative · entry 4

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,897

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
March 25, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,142 $0.00 $0.00
Disclosure

SEC source: 0001816160-26-000003 · form4-03262026_080304.xml · derivative · entry 7

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,284

Underlying: Common Stock · 2,142 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,142 Not disclosed Not disclosed
Disclosure

SEC source: 0001816160-26-000003 · form4-03262026_080304.xml · nonDerivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 833 $21.47 $17,884.51
Disclosure

SEC source: 0001816160-26-000003 · form4-03262026_080304.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,852

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
March 24, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,627 $0.00 $0.00
Disclosure

SEC source: 0001816160-26-000003 · form4-03262026_080304.xml · derivative · entry 6

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,883

Underlying: Common Stock · 1,627 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026.

Read SEC document
March 24, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,627 Not disclosed Not disclosed
Disclosure

SEC source: 0001816160-26-000003 · form4-03262026_080304.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,685

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 06, 2026 Filed Mar 10, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 6,332 $0.00 $0.00
Disclosure

SEC source: 0001816160-26-000002 · form4-03102026_060314.xml · derivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,332

Underlying: Common Stock · 6,332 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027.

Read SEC document
March 06, 2026 Filed Mar 10, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Option (Right to Buy) · Derivative 21,766 $0.00 Strike: $22.16 $0.00
Disclosure

SEC source: 0001816160-26-000002 · form4-03102026_060314.xml · derivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,766

Underlying: Common Stock · 21,766 shares

Expires 2036-03-05

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
November 18, 2025 Filed Nov 19, 2025 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 4,084 $23.69 $96,753.64
Disclosure

SEC source: 0001816160-25-000004 · form4-11192025_061101.xml · nonDerivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,058

F3 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.69 to $23.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 3,966 $0.00 $0.00
Disclosure

SEC source: 0001816160-25-000004 · form4-11192025_061101.xml · derivative · entry 5

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,966 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

F6 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 3,966 $0.00 $0.00
Disclosure

SEC source: 0001816160-25-000004 · form4-11192025_061101.xml · derivative · entry 4

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,966 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 3,966 Not disclosed Not disclosed
Disclosure

SEC source: 0001816160-25-000004 · form4-11192025_061101.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,142

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 3,966 Not disclosed Not disclosed
Disclosure

SEC source: 0001816160-25-000004 · form4-11192025_061101.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 815 shares of the Issuer's common stock acquired by the reporting person on November 14, 2025 pursuant to an employee stock purchase plan.

Read SEC document
May 16, 2025 Filed May 20, 2025 00:52 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 2,000 $20.00 $40,000.00
Disclosure

SEC source: 0001415889-25-013742 · form4-05202025_120553.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,395

F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2024.

Read SEC document
May 16, 2025 Filed May 20, 2025 00:52 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 2,000 $25.00 $50,000.00
Disclosure

SEC source: 0001415889-25-013742 · form4-05202025_120553.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,395

F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2024.

F2 · balance_after: Includes 869 shares of the Issuer's common stock acquired by the Reporting Person on May 15, 2025 pursuant to an employee stock purchase plan.

Read SEC document
May 02, 2025 Filed May 3, 2025 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,327 $14.60 $19,374.20
Disclosure

SEC source: 0001415889-25-011875 · form4-05032025_120531.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,526

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
May 01, 2025 Filed May 3, 2025 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,596 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-011875 · form4-05032025_120531.xml · derivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,192

Underlying: Common Stock · 2,596 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Read SEC document
May 01, 2025 Filed May 3, 2025 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,596 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-011875 · form4-05032025_120531.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,853

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
April 08, 2025 Filed Apr 8, 2025 23:38 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,028 $14.82 $15,234.96
Disclosure

SEC source: 0001415889-25-010423 · form4-04082025_110455.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,257

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
April 05, 2025 Filed Apr 8, 2025 23:38 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,010 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-010423 · form4-04082025_110455.xml · derivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,010

Underlying: Common Stock · 2,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2025 Filed Apr 8, 2025 23:38 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,010 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-010423 · form4-04082025_110455.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,285

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 26, 2025 Filed Mar 27, 2025 00:10 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,095 $17.05 $18,669.75
Disclosure

SEC source: 0001415889-25-009075 · form4-03272025_120357.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,275

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
March 25, 2025 Filed Mar 27, 2025 00:10 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,142 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-009075 · form4-03272025_120357.xml · derivative · entry 5

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,426

Underlying: Common Stock · 2,142 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

Read SEC document
March 25, 2025 Filed Mar 27, 2025 00:10 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,142 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-009075 · form4-03272025_120357.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,370

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 24, 2025 Filed Mar 27, 2025 00:10 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 6,510 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-009075 · form4-03272025_120357.xml · derivative · entry 4

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,510

Underlying: Common Stock · 6,510 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026.

Read SEC document
March 24, 2025 Filed Mar 27, 2025 00:10 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Option (Right to Buy) · Derivative 22,152 $0.00 Strike: $17.23 $0.00
Disclosure

SEC source: 0001415889-25-009075 · form4-03272025_120357.xml · derivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,152

Underlying: Common Stock · 22,152 shares

Expires 2035-03-23

F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
February 24, 2025 Filed Feb 25, 2025 23:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 475 $19.96 $9,481.00
Disclosure

SEC source: 0001415889-25-005575 · form4-02252025_110245.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,228

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
February 23, 2025 Filed Feb 25, 2025 23:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 840 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-005575 · form4-02252025_110245.xml · derivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 840 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

Read SEC document
February 23, 2025 Filed Feb 25, 2025 23:48 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 840 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-005575 · form4-02252025_110245.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
November 19, 2024 Filed Nov 20, 2024 01:41 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 4,073 $16.81 $68,467.13
Disclosure

SEC source: 0001415889-24-027293 · form4-11202024_011147.xml · nonDerivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,863

F3 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.768 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:41 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 3,965 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-027293 · form4-11202024_011147.xml · derivative · entry 5

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,966

Underlying: Common Stock · 3,965 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

F6 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:41 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 3,965 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-027293 · form4-11202024_011147.xml · derivative · entry 4

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,966

Underlying: Common Stock · 3,965 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:41 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 3,965 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-027293 · form4-11202024_011147.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,936

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:41 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 3,965 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-027293 · form4-11202024_011147.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,971

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 836 shares and 800 shares of the Issuer's common stock acquired by the reporting person on May 15, 2024 and November 15, 2024, respectively, pursuant to an employee stock purchase plan.

Read SEC document
May 02, 2024 Filed May 3, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,326 $16.94 $22,462.44
Disclosure

SEC source: 0001415889-24-012236 · form4-05032024_060507.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,370

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.94 to $17.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
May 01, 2024 Filed May 3, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,596 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-012236 · form4-05032024_060507.xml · derivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,788

Underlying: Common Stock · 2,596 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Read SEC document
May 01, 2024 Filed May 3, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,596 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-012236 · form4-05032024_060507.xml · nonDerivative · entry 1

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,696

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
April 08, 2024 Filed Apr 9, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 762 $17.87 $13,616.94
Disclosure

SEC source: 0001415889-24-010602 · form4-04092024_060403.xml · nonDerivative · entry 4

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,100

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.7267 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
April 08, 2024 Filed Apr 9, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,028 $17.87 $18,370.36
Disclosure

SEC source: 0001415889-24-010602 · form4-04092024_060403.xml · nonDerivative · entry 3

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,862

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.763 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
April 07, 2024 Filed Apr 9, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,489 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-010602 · form4-04092024_060403.xml · derivative · entry 6

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024.

F6 · derivative.expiration_date: 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024.

Read SEC document
April 07, 2024 Filed Apr 9, 2024 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,489 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-010602 · form4-04092024_060403.xml · nonDerivative · entry 2

Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,890

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.